XETR
AFX
Market cap2.93bUSD
Jul 10, Last price
30.60EUR
1D
4.51%
1Q
17.96%
Jan 2017
-12.57%
IPO
19.77%
Name
Carl Zeiss Meditec AG
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Carl Zeiss Meditec AG functions as a prominent global medical technology firm, conducting its operations across Germany, other European nations, the United States, and various Asian markets. Its business is organized into two principal divisions: Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment provides an array of products and solutions tailored for the diagnosis and therapeutic management of ocular conditions, including specialized systems and essential consumables for cataract, retinal, and refractive surgical procedures. This division serves ophthalmologists, optometrists, and medical and surgical professionals in hospitals and ambulatory surgery centers. The Microsurgery segment focuses on delivering advanced visualization tools vital for intricate surgical interventions, additionally supplying specialized solutions for ear, nose, and throat (ENT), plastic and reconstructive, dental, and spinal surgeries. This segment supports a diverse group of medical practitioners across various disciplines, as well as healthcare institutions. Established in 1846 and headquartered in Jena, Germany, the company operates as a subsidiary of Carl Zeiss AG.
IPO date
Mar 20, 2000
Employees
4,224
Domiciled in
DE
Incorporated in
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | 2016‑09 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||